SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Grazoprevir / Elbasvir Formulation

Version 3.13  Revision Date: 02.10.2020  SDS Number: 76519-00019  Date of last issue: 23.03.2020

Date of first issue: 17.03.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name : Grazoprevir / Elbasvir Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company : MSD
Innishannon
County Cork - Ireland

Telephone : 353 214329300
Telefax : 908-735-1496
E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Long-term (chronic) aquatic hazard, Category 1
H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements
Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms :

Signal word : Warning
Hazard statements : H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements :
Prevention:
P273 Avoid release to the environment.
Response:
P391 Collect spillage.
2.3 Other hazards
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grazoprevir</td>
<td>1350462-55-3</td>
<td></td>
<td></td>
<td>STOT RE; H373 (Liver, Testis)</td>
<td>&gt;= 1 - &lt; 10</td>
</tr>
<tr>
<td></td>
<td>Elbasvir</td>
<td>1370468-36-2</td>
<td></td>
<td></td>
<td>Aquatic Chronic; H410</td>
<td>&gt;= 2.5 - &lt; 10</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
### SAFETY DATA SHEET
generated according to Regulation (EC) No. 1907/2006

**Grazoprevir / Elbasvir Formulation**

**Version** 3.13  **Revision Date:** 02.10.2020  **SDS Number:** 76519-00019  **Date of last issue:** 23.03.2020  **Date of first issue:** 17.03.2015

<table>
<thead>
<tr>
<th>4.2 Most important symptoms and effects, both acute and delayed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risks</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4.3 Indication of any immediate medical attention and special treatment needed</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treatment</strong></td>
</tr>
</tbody>
</table>

#### SECTION 5: Firefighting measures

<table>
<thead>
<tr>
<th>5.1 Extinguishing media</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Suitable extinguishing media</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5.2 Special hazards arising from the substance or mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Specific hazards during firefighting</strong></td>
</tr>
<tr>
<td><strong>Hazardous combustion products</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5.3 Advice for firefighters</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Special protective equipment for firefighters</strong></td>
</tr>
<tr>
<td><strong>Specific extinguishing methods</strong></td>
</tr>
</tbody>
</table>

#### SECTION 6: Accidental release measures

<table>
<thead>
<tr>
<th>6.1 Personal precautions, protective equipment and emergency procedures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Personal precautions</strong></td>
</tr>
</tbody>
</table>
6.2 Environmental precautions

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment,
appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage areas and containers: Keep in properly labelled containers. Store in accordance with the particular national regulations.
Advice on common storage: Do not store with the following product types: Strong oxidizing agents

7.3 Specific end use(s)
Specific use(s): No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

### Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>OELV - 8 hrs (TWA)</td>
<td>10 mg/m³</td>
<td>IE OEL</td>
</tr>
<tr>
<td>Grazoprevir</td>
<td>1350462-55-3</td>
<td>TWA</td>
<td>25 µg/m³ (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td>Elbasvir</td>
<td>1370468-36-2</td>
<td>TWA</td>
<td>100 µg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>OELV - 8 hrs (TWA)</td>
<td>10 mg/m³</td>
<td>IE OEL</td>
</tr>
</tbody>
</table>

Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used.

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>2068.62 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>2068.62 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Long-term systemic effects</td>
<td>295.52 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Skin contact</td>
<td>Acute systemic effects</td>
<td>295.52 mg/kg bw/day</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>443.28 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Consumers</td>
<td>Inhalation</td>
<td>Acute systemic effects</td>
<td>443.28 mg/m³</td>
</tr>
</tbody>
</table>
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Grazoprevir / Elbasvir Formulation

Version 3.13  Revision Date: 02.10.2020  SDS Number: 76519-00019  Date of last issue: 23.03.2020

<table>
<thead>
<tr>
<th>Consumers</th>
<th>Skin contact</th>
<th>Long-term systemic effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>126.65 mg/kg bw/day</td>
</tr>
<tr>
<td>Consumers</td>
<td>Skin contact</td>
<td>Acute systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
<tr>
<td>Consumers</td>
<td>Ingestion</td>
<td>Long-term systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
<tr>
<td>Consumers</td>
<td>Ingestion</td>
<td>Acute systemic effects</td>
<td>126.65 mg/kg bw/day</td>
</tr>
</tbody>
</table>

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sodium chloride</td>
<td>Fresh water</td>
<td>5 mg/l</td>
</tr>
<tr>
<td></td>
<td>Sewage treatment plant</td>
<td>500 mg/l</td>
</tr>
<tr>
<td></td>
<td>Soil</td>
<td>4.86 mg/kg dry weight (d.w.)</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

Engineering measures
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material: Chemical-resistant gloves

Remarks: Consider double gloving.

Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143

Filter type: Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance: powder
## Grazoprevir / Elbasvir Formulation

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Colour</strong></td>
<td>white</td>
</tr>
<tr>
<td><strong>Odour</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Odour Threshold</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>pH</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Melting point/freezing point</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Initial boiling point and boiling range</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Flash point</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Evaporation rate</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Flammability (solid, gas)</strong></td>
<td>May form explosive dust-air mixture during processing, handling or other means.</td>
</tr>
<tr>
<td><strong>Upper explosion limit / Upper flammability limit</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Lower explosion limit / Lower flammability limit</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Vapour pressure</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Relative vapour density</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Relative density</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Density</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Solubility(ies)</strong></td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Auto-ignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Decomposition temperature</strong></td>
<td>No data available</td>
</tr>
<tr>
<td><strong>Viscosity</strong></td>
<td></td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>Not applicable</td>
</tr>
<tr>
<td><strong>Explosive properties</strong></td>
<td>Not explosive</td>
</tr>
<tr>
<td><strong>Oxidizing properties</strong></td>
<td>The substance or mixture is not classified as oxidizing.</td>
</tr>
</tbody>
</table>

### 9.2 Other information

- **Flammability (liquids)**: No data available
- **Particle size**: No data available
SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Grazoprevir:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg

Elbasvir:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
LD50 (Mouse): > 1,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Grazoprevir:
Result: No skin irritation
Grazoprevir / Elbasvir Formulation

Elbasvir:
Species : reconstructed human epidermis (RhE)
Result : No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:
Grazoprevir:
Species : Bovine cornea
Result : No eye irritation

Elbasvir:
Species : Bovine cornea
Result : No eye irritation

Respiratory or skin sensitisation
Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:
Grazoprevir:
Test Type : Local lymph node assay (LLNA)
Exposure routes : Dermal
Result : Not a skin sensitizer.

Elbasvir:
Test Type : Local lymph node assay (LLNA)
Exposure routes : Dermal
Species : Mouse
Result : negative

Germ cell mutagenicity
Not classified based on available information.

Components:
Grazoprevir:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro
Result: negative
<table>
<thead>
<tr>
<th>Component</th>
<th>Genotoxicity in vivo</th>
<th>Germ cell mutagenicity- Assessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Grazoprevir</td>
<td>Test Type: In vivo micronucleus test</td>
<td>Weight of evidence does not support classification as a germ cell mutagen.</td>
</tr>
<tr>
<td>Elbasvir</td>
<td>gravitational test</td>
<td>Weight of evidence does not support classification as a germ cell mutagen.</td>
</tr>
<tr>
<td>Carcinogenicity</td>
<td>Not classified based on available information.</td>
<td></td>
</tr>
<tr>
<td>Reproductive toxicity</td>
<td>Not classified based on available information.</td>
<td></td>
</tr>
<tr>
<td>Components</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grazoprevir</td>
<td>Test Type: Fertility</td>
<td></td>
</tr>
<tr>
<td>Effects on fertility</td>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Application Route: Oral</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fertility: NOAEL: 400 mg/kg body weight</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Result: negative</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test Type: Multi-generation study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Application Route: Oral</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Fertility: NOAEL: 400 mg/kg body weight</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Result: No effects on fertility, No effects on foetal development</td>
<td></td>
</tr>
<tr>
<td>Effects on foetal development</td>
<td>Test Type: Embryo-foetal development</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Species: Rat</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Application Route: Oral</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Result: No effects on foetal development</td>
<td></td>
</tr>
</tbody>
</table>
Grazoprevir / Elbasvir Formulation

Result: No effects on foetal development

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Intravenous
Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight
Result: No effects on foetal development

Elbasvir:

Effects on fertility:
Test Type: Fertility/early embryonic development
Species: Rat, male and female
Application Route: Oral
Fertility: NOAEL: 1,000 mg/kg body weight
Result: No effects on fertility

Effects on foetal development:
Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on early embryonic development

Test Type: Embryo-foetal development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight
Result: No effects on early embryonic development

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Components:

Grazoprevir:
Target Organs: Liver, Testis
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Grazoprevir:
Species: Rat
NOAEL: 400 mg/kg
Application Route: Oral
Exposure time: 30 Days
Remarks: No significant adverse effects were reported

Species: Rat
NOAEL: 400 mg/kg
### Grazoprevir / Elbasvir Formulation

<table>
<thead>
<tr>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
<th>Species</th>
<th>NOAEL</th>
<th>LOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Target Organs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral</td>
<td>180 Days</td>
<td>No significant adverse effects were reported</td>
<td>Dog</td>
<td>15 mg/kg</td>
<td>100 mg/kg</td>
<td>Oral</td>
<td>270 Days</td>
<td>Liver, Testis, Blood, Bone marrow, gallbladder, spleen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td>270 Days</td>
<td></td>
<td>Mouse</td>
<td>200 mg/kg</td>
<td>500 mg/kg</td>
<td>Oral</td>
<td>90 Days</td>
<td>Liver, Kidney, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral</td>
<td>30 Days</td>
<td></td>
<td>Dog</td>
<td>20 mg/kg</td>
<td>600 mg/kg</td>
<td>Oral</td>
<td>30 Days</td>
<td>Testis, Blood</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Monkey</td>
<td>10 mg/kg</td>
<td></td>
<td></td>
<td>8 Days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Elbasvir:**

<table>
<thead>
<tr>
<th>Species</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
<th>NOAEL</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>1,000 mg/kg</td>
<td>Oral</td>
<td>180 d</td>
<td>No significant adverse effects were reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dog</td>
<td>1,000 mg/kg</td>
<td>Oral</td>
<td>270 d</td>
<td>No significant adverse effects were reported</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure**

**Components:**

**Grazoprevir:**

- Ingestion: Symptoms: Headache, Gastrointestinal disturbance

**Elbasvir:**

- Ingestion:
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Grazoprevir / Elbasvir Formulation

SECTION 12: Ecological information

12.1 Toxicity

Components:

Grazoprevir:

Toxicity to fish

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

LC50 (Americamysis): 8.9 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l
Exposure time: 72 hrs
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 10 mg/l
Exposure time: 72 hrs
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms

EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1.3 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity)

NOEC: 0.98 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)

NOEC: 5 mg/l
Exposure time: 21 d
ic toxicity)
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Elbasvir:
Toxicity to fish
: LC50 (Lepomis macrochirus (Bluegill sunfish)): > 10 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Species: Menidia beryllina (Silverside)
LC50: > 10 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates
: EC50 (Daphnia magna (Water flea)): > 10 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

Species: Americamysis
LC50: 7.7 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants
: EC50 (Pseudokirchneriella subcapitata (algae)): > 0.081 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.081 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms
: EC50: > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 271.9 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity)
: NOEC: 0.0023 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)
: NOEC: 0.84 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211
Grazoprevir / Elbasvir Formulation

Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 10

12.2 Persistence and degradability

Components:

Grazoprevir:
Biodegradability : Result: Not readily biodegradable.
Biodegradation: 66 %
Exposure time: 28 d

Elbasvir:
Biodegradability : Result: Not readily biodegradable.
Biodegradation: 37 %
Exposure time: 28 d

12.3 Bioaccumulative potential

Components:

Grazoprevir:
Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 7.62

Partition coefficient: n-octanol/water : log Pow: 3.72

Elbasvir:
Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 82
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 6.54

12.4 Mobility in soil

Components:

Grazoprevir:
Distribution among environmental compartments : log Koc: 4.01

Elbasvir:
Distribution among environmental compartments : log Koc: 5.24

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available
SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number

<table>
<thead>
<tr>
<th>ADN</th>
<th>UN 3077</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>UN 3077</td>
</tr>
<tr>
<td>RID</td>
<td>UN 3077</td>
</tr>
<tr>
<td>IMDG</td>
<td>UN 3077</td>
</tr>
<tr>
<td>IATA</td>
<td>UN 3077</td>
</tr>
</tbody>
</table>

14.2 UN proper shipping name

<table>
<thead>
<tr>
<th>ADN</th>
<th>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)</td>
</tr>
<tr>
<td>RID</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)</td>
</tr>
<tr>
<td>IMDG</td>
<td>ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Elbasvir)</td>
</tr>
<tr>
<td>IATA</td>
<td>Environmentally hazardous substance, solid, n.o.s. (Elbasvir)</td>
</tr>
</tbody>
</table>

14.3 Transport hazard class(es)

<table>
<thead>
<tr>
<th>ADN</th>
<th>9</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADR</td>
<td>9</td>
</tr>
<tr>
<td>RID</td>
<td>9</td>
</tr>
<tr>
<td>IMDG</td>
<td>9</td>
</tr>
<tr>
<td>IATA</td>
<td>9</td>
</tr>
</tbody>
</table>

14.4 Packing group
ADN
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG
Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft) : 956
Packing instruction (LQ) : Y956
Packing group : III
Labels : Miscellaneous

14.5 Environmental hazards

ADN
Environmentally hazardous : yes

ADR
Environmentally hazardous : yes

RID
Environmentally hazardous : yes

IMDG
Marine pollutant : yes

IATA (Passenger)
Environmentally hazardous : yes

IATA (Cargo)
Environmentally hazardous : yes
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Grazoprevir / Elbasvir Formulation

Version: 3.13  Revision Date: 02.10.2020  SDS Number: 76519-00019  Date of last issue: 23.03.2020
Date of first issue: 17.03.2015

14.6 Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

<table>
<thead>
<tr>
<th>Class</th>
<th>ENVIRONMENTAL HAZARDS</th>
<th>Quantity 1</th>
<th>Quantity 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>E1</td>
<td></td>
<td>100 t</td>
<td>200 t</td>
</tr>
</tbody>
</table>

The components of this product are reported in the following inventories:
AICS : not determined
DSL : not determined
IECSC : not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H373: May cause damage to organs through prolonged or repeated exposure if swallowed.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Grazoprevir / Elbasvir Formulation

Version 3.13 Revision Date: 02.10.2020 SDS Number: 76519-00019 Date of last issue: 23.03.2020
Date of first issue: 17.03.2015

H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations
Aquatic Chronic : Long-term (chronic) aquatic hazard
STOT RE : Specific target organ toxicity - repeated exposure
IE OEL : Ireland. List of Chemical Agents and Occupational Exposure Limit Values - Schedule 1
IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Classification of the mixture: Aquatic Chronic 1
Classification procedure: Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only
Grazoprevir / Elbasvir Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.13</td>
<td>02.10.2020</td>
<td>76519-00019</td>
<td>23.03.2020</td>
<td>17.03.2015</td>
</tr>
</tbody>
</table>

Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN